Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASO207 Injection in Subjects With Relapsed/Refractory B-cell Malignancies
NCT07574346Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2026
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IASO207 in B-cell malignancy, sponsored by Peking University People's Hospital. Primary endpoints: Adverse Events up to 2 years, Dose-Limiting Toxicity up to 28 days and 1 more. Started May 2026; status: recruiting.
02
Drugs
IASO207
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07574346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07574346.